Literature DB >> 30624370

The global burden of hypertension exceeds 1.4 billion people: should a systolic blood pressure target below 130 become the universal standard?

Brent M Egan1, Sverre E Kjeldsen2, Guido Grassi3,4, Murray Esler5, Guiseppe Mancia6.   

Abstract

: In 2010, 1.4 billion people globally had hypertension, with 14% controlled to systolic blood pressure (SBP, mmHg) below 140, which contributes to 18 million cardiovascular deaths annually. Recent hypertension guidelines endorsed SBP targets below 130 or lower for all or some hypertensive patients to reduce cardiovascular events (CVEs) more than the prior SBP target less than 140. In 2016, the Australian Guideline strongly recommended target SBP below 120 for adults at very high risk for CVE or aged above 75 years. In 2017 and 2018, the Canadian Guideline recommended automated office SBP (AOSBP) below 120 in adults at high risk and aged above 75 years (grade B). In 2017, the US Guideline recommended SBP below 130 for all adults (moderate-to-high risk class I; lower-risk grade IIb). In 2018, the European Guideline recommended SBP below 140 for all adults, and, if tolerated, a SBP range of 120-129 for adults aged below 65 years and 130-139 for adults aged at least 65 years (class I). The guidelines were variably influenced by Systolic blood PRessure INTervention trial and meta-analyses indicating fewer CVE when mean in-trial SBP was below 130 versus above 130. Clinicians considering lower SBP targets should be aware that: AOSBP preceded by 5-min rest is approximately 10-15 mmHg lower than usual office SBP; hypertensive patients with office SBP consistently versus intermittently below 140 have fewer CVE; benefits of mean office SBP or AOSBP below 120 remain unproven and could increase adverse events. Clinicians worldwide will do well to control SBP to below 140 in most hypertensive patients on most visits, which should lead to mean in-clinic SBP of 120-129.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30624370     DOI: 10.1097/HJH.0000000000002021

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  23 in total

1.  Blood Pressure Targets Achievement According to 2018 ESC/ESH Guidelines in Three European Excellence Centers for Hypertension.

Authors:  Giuliano Tocci; Vivianne Presta; Claudio Ferri; Josep Redon; Massimo Volpe
Journal:  High Blood Press Cardiovasc Prev       Date:  2020-01-08

Review 2.  Certain beta blockers (e.g., bisoprolol) may be reevaluated in hypertension guidelines for patients with left ventricular hypertrophy to diminish the ventricular arrhythmic risk.

Authors:  Goran Koracevic; Milovan Stojanovic; Dragan Lovic; Marija Zdravkovic; Dejan Sakac
Journal:  J Hum Hypertens       Date:  2021-03-02       Impact factor: 3.012

3.  PTML modeling for peptide discovery: in silico design of non-hemolytic peptides with antihypertensive activity.

Authors:  Valeria V Kleandrova; Julio A Rojas-Vargas; Marcus T Scotti; Alejandro Speck-Planche
Journal:  Mol Divers       Date:  2021-11-21       Impact factor: 3.364

Review 4.  Sex Differences in Cardiovascular Consequences of Hypertension, Obesity, and Diabetes: JACC Focus Seminar 4/7.

Authors:  Judith G Regensteiner; Jane E B Reusch
Journal:  J Am Coll Cardiol       Date:  2022-04-19       Impact factor: 27.203

Review 5.  Circadian Rhythm, Clock Genes, and Hypertension: Recent Advances in Hypertension.

Authors:  Hannah M Costello; Michelle L Gumz
Journal:  Hypertension       Date:  2021-10-04       Impact factor: 10.190

Review 6.  Artificial Intelligence and Hypertension: Recent Advances and Future Outlook.

Authors:  Thanat Chaikijurajai; Luke J Laffin; Wai Hong Wilson Tang
Journal:  Am J Hypertens       Date:  2020-11-03       Impact factor: 3.080

7.  Antihypertensive Indigenous Lebanese Plants: Ethnopharmacology and a Clinical Trial.

Authors:  Ali A Samaha; Mirna Fawaz; Ali Salami; Safaa Baydoun; Ali H Eid
Journal:  Biomolecules       Date:  2019-07-20

8.  Efficacy of Text Messaging and Personal Consultation by Pharmacy Students Among Adults With Hypertension: Randomized Controlled Trial.

Authors:  Panpan Zhai; Khezar Hayat; Wenjing Ji; Qian Li; Li Shi; Naveel Atif; Sen Xu; Pengchao Li; Qianqian Du; Yu Fang
Journal:  J Med Internet Res       Date:  2020-05-20       Impact factor: 5.428

9.  Molecular Basis for Omapatrilat and Sampatrilat Binding to Neprilysin-Implications for Dual Inhibitor Design with Angiotensin-Converting Enzyme.

Authors:  Urvashi Sharma; Gyles E Cozier; Edward D Sturrock; K Ravi Acharya
Journal:  J Med Chem       Date:  2020-05-08       Impact factor: 7.446

10.  Death burden of high systolic blood pressure in Sichuan Southwest China 1990-2030.

Authors:  Zhuo Wang; Yu Luo; Shujuan Yang; Mingliang Zuo; Rong Pei; Jun He; Yin Deng; Maigeng Zhou; Li Zhao; Hui Guo; Kun Zou
Journal:  BMC Public Health       Date:  2020-03-29       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.